Embryogenesis
Introduction
Understanding the regulation of gene expression is arguably the most crucial basic question of biology. In this field, transcription of protein-encoding genes by RNA polymerase II receives most attention. This exceedingly complex control mechanism involves several different protein complexes binding to target promoter regions, which include, in addition to sequence-and cell-specific transcription factors, a number of non-DNA binding coactivators, the Negative Cofactor NC2, the TBP-associated factors (TAFs) present in basal transcription factor TFIID, other basal factors like TFIIA, TFIIB, TFIIF, TFIIE and TFIIH, and the mediator complex (Thomas and Chiang, 2006) .
The basic mechanisms underlying these processes appear to be highly conserved throughout the superkingdom Eukarya, which has allowed using yeast as a simple and accessible model system to investigate the principles of gene transcription. Identification of many of the factors involved in transcription, as well as details on how they interact have thus been identified originally in human and in yeast cells. The TATA-binding protein (TBP) is a highly conserved protein and has been shown to be essential in yeast cells and mouse embryos. It has a particularly pivotal role in control of RNA 0925-4773/$ -see front matter Ó 2011 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2011.03.002 polymerase II-transcribed genes. Originally named for its binding to TATA-box containing promoters, it is now known to be essential for transcription by all three eukaryotic nuclear RNA polymerases including RNA polymerase II-transcribed genes either containing or lacking a TATA-box. It may be present in one of two distinct complexes, TFIID and B-TFIID, of which the latter contains a specific TAF, BTAF1 in mammals or its ortholog Mot1p in yeast. These evolutionary highly conserved transcription factors are members of the SNF2-like family of ATPases. BTAF1's capability of ATP hydrolysis is essential for its influence on the dynamics of TBP-promoter interactions (Auble, 2009; Klejman et al., 2004 Klejman et al., , 2005 Tora and Timmers, 2010; Van Der Knaap et al., 2000) . BTAF1 interacts directly with TBP through HEAT/ARM repeats in the N-terminal 600 amino acids of the protein (Klejman et al., 2005) , whereas the ATPase domain resides in the carboxyl terminus. The molecular biology of BTAF1 and its role in the basic transcription complexes has been the subject of many studies in the past decade. Here we report the consequences of loss of function of mouse Btaf1 in embryonic development: mutant embryos homozygous for a, presumably hypomorphic, mutant allele of the Btaf1 gene died around embryonic day (E) 9.5 with various malformations. Analyses in vitro strongly indicate that the altered protein has lost stability as well as functional effectiveness. Tentative transcript profiling analysis indicated that a considerable number of genes linked to hematopoiesis, heart formation and related functions were down-regulated in mutant embryos.
Results

Isolation and identification of Btaf1 mutant
In a chemical mutagenesis screen for developmental defects (Wansleeben et al., 2010a, b) , one mutant line was identified on the basis of growth retardation and extreme cardiac edema at E10.5. These lethal abnormalities were already perceptible at E9.5 ( Fig. 1A and B) . In addition to cardiac abnormalities accompanied by disturbed blood circulation, head and brain development appeared to be delayed. Histological sections demonstrated incomplete trabeculation of the heart and underdevelopment of the brain ( Fig. 1E and F) .
Genetic linkage mapping by means of SNP genotyping led to the identification of a 4.5-Mb segment on chromosome 19 that contained 61 genes, 41 of which being protein-coding genes. This allowed us to proceed with sequencing of coding regions, including intron/exon transitions, of the candidate genes in this region, which resulted in the discovery of a mutation in the Btaf1 gene ( Fig. 2A) . Homozygosity for this mutation correlated completely with occurrence of the phenotype in over hundred embryos observed.
The G-to-A transition discovered in Btaf1 exon 28, at position 4299 of the cDNA (ENSMUST00000099494), leads to a predicted valine-to methionine substitution at position 1330 (ENSMUSP00000097093) within the ATPase domain (Prosite Accession PS51192; all ID numbers see www.ensembl.org) of the Btaf1 protein (Fig. 2B) . The strong evolutionary conservation of this protein domain is demonstrated in Fig. 2C , comparing the mouse Btaf1 ATPase domain to those encoded by its chicken, zebrafish, fruitfly and yeast orthologs. An identity of 175 out of 176 amino acids is seen with the ATPase domain in human BTAF1, on which so far virtually all biochemical work with animal BTAF1 has been based. Residue V1330 is quite conservatively replaced by isoleucine in Saccharomyces cerevisiae MOT1p as well as in a number of related helicaselike ATPases including the human nucleotide excision repair protein ERCC6 and zebrafish and human RAD54.
To address the possibility that in this random screen one or more other mutated genes contributed to the phenotype, we analyzed an independent Btaf1 mutant. We generated a second mutant line by injection of mutant ES cells into blastocysts. These ES cells carry a mutant allele in which Btaf1 was expected to be inactivated by the insertion of a gene-trap construct (IGTC clone RRF308; see also http://www.informatics. jax.org/javawi2/servlet/WIFetch?page=alleleDetail&key=3434 44 and Friedel et al., 2005) . We then crossed the resulting Btaf1 RRF308/+ mice to Btaf1 V1330M/+ mice and analyzed E9.5 embryos that were heterozygous for both alleles. In agreement with the suspicion that the Btaf1 mutant allele is responsible for the phenotype, these transheterozygotes had a strongly affected phenotype. Embryos seemed growth-arrested and edematous at stages around E8.0. This phenotype resembles the one in Btaf1 V1330M double mutants. The phenotype appeared in these crosses with a frequency as expected for Mendelian inheritance and correlated completely with the genotype of transheterozygous embryos (Fig. 1C) . The observation that embryos homozygous for the gene-trap allele appeared to have even more growth retardation (Fig. 1D ) further supports the view that the gene-trap mutant allele is less functional than the V1330M allele. We conclude from these data that the point mutation described above is responsible for the affected phenotype of the Btaf V1330M mice and that the latter is probably a hypomorphic mutation.
Expression of Btaf1 in mouse embryos
The function of BTAF1 and of other TAFs has been extensively studied in a biochemical and cellular context, but knowledge on its function in vivo is limited. To begin such an analysis, we looked into the expression pattern of Btaf1 during embryonic development. We also included in situ hybridizations with a probe for TBP, in view of the important biological function of complexes containing both factors. Not unexpectedly, given their assumed general role in gene transcription, we observed in hybridization in situ on sections that Btaf1 and Tbp transcripts are omnipresent in embryos of E8.5 and E9.5 (see Supplementary Fig. 1 ).
Expression of Btaf1 in mutants
To investigate a possible impact of the mutation in Btaf1 on its expression level, we first compared protein extracts of wildtype versus mutant embryos. Protein was isolated from pools of genotyped embryos, and subjected to Western analysis using a monoclonal antibody generated against human BTAF1, which is known to cross-react with mouse Btaf1. Standard PAGE analysis showed that the migration rate of the protein in the gel was indistinguishable between wildtype and mutant form, but the concentration of Btaf1 protein in the extracts from mutant E8.5 and E9.5 embryos was at most 10% of that in wildtypes (Fig. 3A and data not shown). Apparently, for reasons not directly obvious, Btaf1 does not accumulate to its normal levels in the mutant, while TBP levels appear to be higher in the mutant extracts. In spite of the fact that nonsense mediated decay (Stalder and Muhlemann, 2008) is not expected to occur in this mutant allele, we nevertheless verified by means of quantitative PCR (qPCR) the concentrations of Btaf1 mRNA in mutant and wildtype-embryo extracts. No significant change in expression levels was seen (see Fig. 3B ), indicating that the lower protein levels must be caused by either less efficient mRNA translation or, more likely, decreased stability of the protein.
Downstream effects of Btaf1 loss-of-function
To investigate the downstream consequences of Btaf1 loss of function, we performed a transcription profiling experiment. By means of a microarray screen, we compared mRNA transcripts from pools of Btaf1 À/À and Btaf1 +/+ embryos.
Where possible, we used 3-5-somite embryos, a stage we considered to be immediately prior to the emergence of a perceptible phenotype. The experiments were done in duplo, i.e. two sets of comparisons were made: in one case stage matching (i.e. number of somites counted) was the highest priority, in the other case age matching: these pools were designed such that a maximum number of litter mates were compared while have not yet turned. (E and F) histological sections of E9.5 wildtype and mutant, demonstrating cardiac and brain abnormalities. V1330M refers to the allele identified in the ENU screen; RRF308 refers to the allele originating from the RRF308 ES cell line. Abbreviations: a, atrium; fb, forebrain; fl, fore limb; h, heart; hb, hindbrain; hl, hind limb; ha, hyoid (2nd) arch; ma, mandibular arch; nt, neural tube; som, somites; v, ventricle; WT, wildtype.
a difference of up to five somites was allowed. The data obtained in this way were generally very similar for both types of comparison. Data that were not or unsatisfactorily confirmed by the duplo experiments were disregarded. A subset of genes found to be significantly up-or down-regulated was analyzed by quantitative PCR on cDNA isolated from independent sets of embryos, which in a number of cases did not convincingly confirm the results from the microarray. Microarray data have been deposited in Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/ Protein levels were analyzed in total lysates of wildtype and mutant embryos at E8.5 and E9.5 as depicted. Lysate prepared from human U2OS cells was loaded on the gel as a control. Protein levels were analyzed by immunoblotting with BTAF1, TAF5, TBP and GAPDH antibodies. Note that TBP is up-regulated in mutant lysates. (B) cDNA was prepared from both wildtype and mutant embryos at E9.5. mRNA levels of Btaf1, PPIA and B2M were analyzed by quantitative PCR. Depicted is an average of four experiments, Btaf1 mRNA levels are plotted relative to PPIA or B2M mRNA levels, as indicated.
projects/geo); Accession Code GSE26743. A selection of the results of the comparison is shown in Table 1 where most of the genes up-or down-regulated by at least a factor log 1.8 are listed, after applying the criteria described above.
Given the general character of the function of Btaf1, an impact on a collection of genes with a large variety of functions was expected. To some extent this is what we see in Table 1 . Nevertheless, a considerable number of genes functionally related to heart development or hematopoiesis are seen to be down-regulated in the mutant. Secondly, the number of genes significantly down-regulated in the mutant appears to be greater than of those up-regulated. Although this might seem to suggest a net positive function of Btaf1 in transcription at this stage, obviously genes with changed expression are not necessarily direct targets of Btaf1. Obviously, genes encoding muscle proteins are in the context of a pre-somite embryo necessarily heart-specific. Examples of down-regulated genes include the two genes encoding Atrial Natriuretic Factor A and B, two genes encoding hemoglobin subunits, the Titin gene, which is related to a function in striated muscle, Connexin40 and the endothelium-specific gene Esm1. The latter gene has been implicated in vasculogenesis and is up-regulated in Hhex mutant embryos that have disturbed vasculogenesis (Cong et al., 2006) .
2.5.
Possible impact of the mutation on the BTAF1 3D structure
The ATPase domains of BTAF1 and its yeast ortholog Mot1p are closely related to that of the RAD54 chromatin remodeling protein. To obtain insight into the molecular consequences of the V1330M mutation we derived a structure for the BTAF1 ATPase domain through a threading approach using the experimental structure of RAD54 from zebrafish (Fig. 4A) . The V1330M mutation in BTAF1 localizes to ATPase domain motif IA (residues 1328-1334: SLVVCPP; b5 in Fig. 4B ), which represents one of the signature motifs of the SNF2 family. This motif maps to the interface of the two helicase lobes and it has been proposed to bind to the ribose and phosphate groups of DNA in SNF2 and RAD54 (Thoma et al., 2005) . Our homology modeling indicated that residue V1330 is located at the end of strand b5 and that it is buried inside the protein (Fig. 4C) . Introduction of the larger methionine side chain in the V1330M mutant can result in steric clashes with the W1340 of helix a6 and, possibly, with V1379 in strand b7 (Fig. 4D ). W1340 is highly conserved in the SNF2 family of ATPases and centrally located in a6. V1379, on the other hand, is only conserved among BTAF1/Mot1 orthologs (Fig. 4B) . Interestingly, V1379 lies in strand b7, which is part of the SNF2-specific element A also proposed to contact DNA (Thoma et al., 2005) . Our analysis indicates that the V1330M mutation destabilizes contacts of strand b5 with helix a6 and strand b7. Possibly this alters the (potential) interactions of BTAF1 with DNA, resulting in a reduced activity of the protein as observed in the FRAP analysis (see below). In addition, the mutation could also lower the overall conformational stability of BTAF1 leading to a decreased expression of the mutant protein as observed after transfection in cells (data not shown) and in the mutant embryos (Fig. 3A) .
Loss of function of the BTAF1 V1330M mutant protein
The ATPase function of BTAF1 and its yeast homolog is involved in regulation of TBP-DNA interactions as has been shown in vitro (Auble et al., 1994; Chicca et al., 1998) . Recently it was shown by using fluorescence recovery after photobleaching (FRAP) in living human cells, that the interaction of TBP with chromatin is regulated by BTAF1 (de Graaf et al., 2010) . Interestingly, when overexpressing or removing BTAF1 from the system, only the chromatin dissociation rate of TBP is affected and no effect is observed on its association rate. In a transient transfection set up, we transfected GFP-TBP in the presence of wildtype BTAF1 or the V1330M mutant in HEK293T cells and subjected the resulting cells to FRAP analysis. As a control we included the D1404N BTAF1 mutant, which is known to be incapable of hydrolyzing ATP in this experiment (Auble et al., 1994) . As shown before (de Graaf et al., 2010) , overexpressing wildtype BTAF1 increased the mobile fraction of GFP-TBP (Fig. 5A) . In contrast, expression of both the V1330M and D1404N mutants did not increase the fraction of mobile GFP-TBP (Fig. 5A) , although the expression of the mutant proteins was comparable to wildtype (Fig. 5B) . It should be noted that more DNA of the mutants needed to be transfected to achieve this equal expression. As in the expression study in embryos (Fig. 3A) , the TBP levels analyzed as control appear to reach higher levels in mutant extracts. The lack of effect on TBP mobility cannot be explained by lack of binding to TBP, as an immunoprecipitation of ectopically co-expressed GFP-TBP and HA-BTAF1 (wildtype and mutants) shows an even enhanced binding of the HA-BTAF1 mutants to GFP-TBP ( Supplementary Fig. 2 ).
In conclusion, the V1330M mutation leads to decreased Btaf1 protein stability as well as to reduced activity in mobilizing TBP from chromatin.
Discussion
In this work we identify a point mutation in the gene encoding the general transcription factor BTAF1 and determine the functional consequences in vivo and in vitro. There is considerable interest in the biochemical details of the RNA polymerase II transcription complexes, as such knowledge is indispensable to understand the exceedingly complex mechanisms underlying transcriptional control in eukaryotes. Therefore, the structure-function relationships of transcription factors like BTAF1 have been studied at the molecular level, including an extensive mutagenesis approach (Klejman et al., 2005) . While it would be impractical to perform such large-scale studies in vivo, our work demonstrates how a phenotype-based mutagenesis approach may provide subtle and biochemically interesting mutants.
We show that a substitution mutation causing a Val to Met substitution in the ATPase domain of BTAF1 results in a severely compromised phenotype in homozygous mutant embryos. At the molecular level the V1330M mutation has quantitative consequences as is evident from the lower amount of BTAF1 protein detected in mutant embryos. Very likely the mutation also has a qualitative impact on the protein as shown by the results of our FRAP analyses that demonstrated impaired capacity of the altered protein to dissociate TBP from chromatin. Interestingly, binding to TBP is not affected, reflecting the specificity of the point mutation. Both in embryos and in the transfection experiments we noted unexpected increased levels of TBP in mutant extracts. Perhaps this is an indication for a negative effect of Btaf1 on TBP stability.
The strong quantitative decrease of the protein in mutant embryos is probably caused by conformational changes leading to a lack of stability, as the alternative, a decrease of translation deficiency caused by the point mutation seems less plausible. The low amount of normal protein at E8.5, combined with the observation of the protein being functionally impaired would suggest that the mutant is either a null or a strong hypomorph. Nevertheless, the apparently stronger phenotype of the gene-trap mutant suggests that an even lower functional level of BTAF1 is possible. It should, however, be noted that mice with quite different genetic backgrounds were compared here, possibly contributing to phenotypic variance.
It might appear surprising that extensive loss of function of a highly conserved component of one of the basal transcription complexes, B-TFIID, supposedly present in most or all living eukaryotic cells, would be compatible with life through gastrulation until an early somite stage, more than 8 days after conception. Possibly, a level of redundancy between different TAFs or reduced NC2 expression might lead to partial compensation for Btaf1's function, even if it is far from obvious to identify a candidate TAF to functionally replace Btaf1. For this as well as other reasons it will be interesting to compare the composition of the B-TFIID complex in the Btaf1 mutant(s) with the normal complex. Alternatively, protein might have been initially normal and instability set off at later stages, for instance due to changing availability of interacting proteins. To study this possibility, biochemical analysis of very early (for instance, E7.5) embryos would be necessary, which is practically infeasible given the required amounts of protein.
Previously the function of a number of the components of the transcription complexes has been studied in mice, usually by standard knockout technology, and these in vivo studies sometimes revealed functions more specific than might have been anticipated. This adds to the increasingly nuanced view of the specific roles of the general transcription machinery Cells were analyzed for FRAP 20 h after transfection. Prior to photobleaching a strip spanning the nucleus was scanned at low laser power. After this, the ROI was scanned every 21 ms until 38 s after bleaching. Raw data were normalized for fluorescence intensity before bleaching and an average of 10 nuclei was plotted. (B) Expression levels of the exogenous protein as described by legend of 5A was analyzed in total lysates by immunoblotting with HA, BTAF1 and GFP antibodies. Note higher expression of pEGFP-TBP in mutant lysates.
once thought to have a predominantly passive role in cellspecific transcription (for a more thorough discussion, see D'Alessio et al., 2009). For instance, inactivation of TBP leads to growth arrest and apoptosis at the blastocyst stage of mouse embryogenesis, but also demonstrated that TBP is specifically needed for de novo initiation of transcription, e.g. in zygotes and during cell proliferation, and not for re-initiation and maintenance of transcription (Martianov et al., 2002) . Furthermore, mice lacking the TBP-related factor TBP2 had a very distinct phenotype: a defect in folliculogenesis leading to female sterility (Gazdag et al., 2009 ). Loss-of-function genetic data obtained for the TFIID component TAF10 were reminiscent of those reported for TBP: using tissue-specific (conditional) knockout technology, it was shown that deficiency of TAF10 in keratinocytes caused failure to terminally differentiate in fetal, but not adult epidermis (Indra et al., 2005) . Moreover, a liver-specific inactivation of the same factor resulted in extensive loss of expression of liver-specific genes during embryogenesis (Tatarakis et al., 2008) , whereas the disintegration of TFIID that results from TAF1-inactivation is compatible with a normal phenotype of adult hepatocytes. The function of the mediator complex that connects transcriptional activators to RNA polymerase II was studied in vivo by knocking out the mediator subunit Med1/TRAP220. Embryos homozygous for this mutation died around E11.5, suffering from heart failure, impaired neuronal development and anemia. The latter could be reconfirmed as a clear link with erythroid development was established as this subunit interacts directly with the erythroid master switch Gata-1 (Stumpf et al., 2006) . Our analyses have not clearly linked the function of Btaf1 to specific developmental processes or molecular pathways. The phenotype is consistent with a rather unspecific effect on growth. Our previous experimental work in which we knocked down human BTAF1 in U2OS and HeLa cells did not provide evidence for a link with cell cycle progression (de Graaf et al., 2010) . To address possibility of any specific functions of Btaf1 in biological processes, it will be indispensable to generate conditional, tissue-or cell-specific mutant alleles. On the short term it will nevertheless also be interesting to investigate further the observed link with genes linked to erythrogenesis, and heart development. Interestingly, the phenotype of loss-of-function mutants of Titin, one of the genes we found to be down-regulated in our microarray analysis is similar to the Btaf1 phenotype, with mutant embryos dying around E9.5 (Weinert et al., 2006) . On the other hand, we cannot exclude the possibility that at the stages analyzed, some or all of the embryos had already a slightly affected morphologic phenotype, making it in principle possible that some of the molecular effects were a consequence of the phenotype, rather than, as is the intention of the experimental approach, a cause.
Our data indicate that more genes are convincingly downregulated than activated in the mutant, arguing for a positive role of Btaf1. Whether Btaf1 acts predominantly as a positive or a negative factor in transcription has been the subject of discussion, but in recent years a pattern has emerged suggesting that Btaf1 would influence the on/off rate of TBP at its target promoters, and the consequence of Btaf1's inactivation might be context-dependent. Studies on BTAF1 have shown that it has both positive and negative effects on transcription, which most likely reflects its function in regulating the dynamic properties of TBP transcription complexes (for a discussion and references, see Auble, 2009; Tora and Timmers, 2010; van Werven et al., 2009 ). More specifically, TATA-containing promoters are often found in regulated and tissue-specific genes, including the cardiogenesis-and hematopoiesis-related genes that are down-regulated in the Btaf1 mutant. Such highly regulated genes are expected to be associated with a dynamic and rapid TBP-promoter dissociation. At a molecular level, the heterodimeric negative factor NC2 is known to assemble with TBP at the promoter precluding the formation of complexes like TFIIA or TFIIB, which prevents formation of a pre-initiation complex. In the NC2-TBP-DNA complex the NC2-TBP appears to wrap around the DNA, and this ring-like structure would be able to slide over the DNA. Interactions of BTAF1/Mot1p with its substrate, the NC2-TBP-DNA complex would catalyze dissociation of the TBP complex, and enhance the turnover of TBP (de Graaf et al., 2010) . This central event in transcriptional gene regulation also involves the transition of TATA-containing DNA form a bent to a non-bent structure. Loss of function of BTAF1 may lead to a more predominant occurrence of TBP-NC2 rings keeping core promoters, and perhaps more specifically those containing a TATA-box, silent. Clearly, this hypothesis needs further testing.
Our paper demonstrates a substantial degree of specificity of an in vivo phenotype of a loss-of-function mutation in a gene that encodes a general transcription factor. In addition it stresses that a random, phenotype-based mutagenesis screen can yield mutant alleles that are of interest both from a biological and a molecular point of view.
4.
Materials and methods
Generation and identification of mutants
Mutants were generated by random chemical mutagenesis and mapped using procedures essentially similar to those used by Kasarskis et al. (1998) , see also Wansleeben et al. (2010a, b) . Briefly, C57BL/6 mice were injected three times with 1-week intervals with 60-80 mg/kg bodyweight of ethyl-Nnitrosurea (ENU), and after approximately 7 weeks of recovery crossed to FVB/N mice. The resulting male ''G1 founders'' were crossed with their daughters and embryos were visually inspected on embryonic day (E) 10.5. A SNP panel distinguishing C57Bl/6 and FVB/N polymorphisms was used for positional cloning of the affected genes. ES cell clone RRF308 (formerly BayGenomics) was obtained from the Mutant Mouse Regional Resource Centre (MMRRC) (University of California at Davis). Cells were grown and used to generate chimeras using standard procedure. Animal experiments were conducted under the approval of the animal care committee of the KNAW.
4.2.
Gene expression analysis 4.2.1. Quantitative PCR RNA was isolated from individually collected embryos of each genotype and stage. RNA was extracted from whole embryos using TRIzol method (Invitrogen, UK) and quantified using NanoDrop analysis (Thermoscientific, USA) according to the manufacturer's instructions. PCR was performed in duplicate in pooled individual samples from each genotype, with 2 ll of amplified cDNA per reaction using Light Cycler DNA Master SYBR Green 1 (Roche) according to manufacturer's instructions. Real time PCR was carried out using the MyiQ PCR equipment (Bio-Rad). Expression of mouse Gapdh, Ppia and b2m was used as internal controls. Relative gene expression was calculated by the comparative 2 ÀDDCT method (Livak and Schmittgen, 2001 ).
Transcription profiling
A microarray screen for genes with altered expression in the Btaf V1330M mutant as compared to WT embryos was performed with RNA from whole embryos as described in the text. Embryos were stored in RNAlater (Ambion, Cat. No. AM1924) and, upon genotyping, pools of approximately six homozygous mutant and wildtype embryos were made. RNA was purified using a kit from Qiagen (Cat. No. 74104). cDNAs were synthesized and Cy-3/Cy-5 labeled cRNAs were generated by using a Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Santa Clara, CA). The labeled cRNAs were hybridized on 4X44K Agilent Whole Mouse Genome Dual Color Microarrays (G4122F). A double dye swap experiment was performed. Microarray signal and background information were retrieved with Feature Extraction (V9.5.3, Agilent Technologies). All data analyses were performed by using ArrayAssist (5.5.1, Stratagene Inc., La Jolla, CA) and Microsoft Excel (Microsoft Corporation, Redmont, WA). Only features with an expression value higher than twice background signal were further analyzed. Genes were considered to be significantly up or down-regulated, respectively, if their linear ratio was higher or lower than 1.5.
In situ hybridization
In situ hybridization on whole or sectioned embryos was by slightly modified standard procedures as described previously (Beverdam et al., 2001; Gregorieff et al., 2004) . To distinguish widespread all-pervading signal from background, control experiments were routinely done with probes known to give distinct patterns, usually for eHand and Sonic hedgehog.
4.3.
Cell lines and transient transfection U2OS and HEK293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, L-glutamine and antibiotics at 37˚C. Transient transfection of plasmid DNA was performed 6 h after seeding using polyethylenimine. Twenty-four hours post-transfection cells were analyzed by fluorescence recovery after photobleaching or harvested for IP and Western blot analysis.
DNA expression constructs
The HA-BTAF1 expression construct pMT2-HA-BTAF1 encodes the human BTAF1 protein fused to a Hemagglutinin tag and was described before (de Graaf et al., 2010) . The point mutations D1404N and V1330M were introduced using site directed mutagenesis. The GFP-TBP expression construct pEG-FP-TBP was described before (Chen et al., 2002) .
Immunoprecipitation and immunoblotting
Cells were lysed in IP lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM KCl, 5 mM MgCl 2 , 0.5 mM EDTA, 0.1% NP40, 10% glycerol and protease inhibitors). Cleared lysate was added to Anti-HA Affinity Matrix (Roche). Precipitated proteins were separated on 10% SDS-PAGE and blotted onto PVDF membranes. The membrane was developed with the appropriate antibodies and ECL (Pierce). Embryo extracts were made by homogenizing the embryos using a 25G needle in IP lysis buffer. Protein amount was determined using Bio-Rad protein assay (based on the method of Bradford).
Strip-FRAP
Cell imaging and FRAP studies were performed using a Zeiss 510 META confocal LSM using the 488 nm laser line of a 200 mW Argon laser with tube current set at 6.1-6.3 A. All images and FRAP results were obtained using a 40· oil immersion lens (NA = 1.3) using filters which pass emission light between 505 and 530 nm. Strip-FRAP was performed as described (de Graaf et al., 2010) . Briefly, a narrow strip ($0.75 lm) spanning the width of the nucleus was monitored every 21 ms using 0.2-0.5% laser power of the 488 nm laser line, an intensity at which no significant monitor bleaching was observed. After 2 s the strip was quickly bleached for 42 ms at maximum laser power. Subsequently, recovery of fluorescence was monitored at 21 ms intervals for 38 s. For quantitative analyses fluorescence intensity in the strip was expressed relatively to the fluorescence before bleaching. For each transfection the average of 10 nuclei were taken.
